Corvus Pharmaceuticals, Inc.
3.90%
3,275,616
1626971
221015100
Jan 22, 2026
Feb 5, 2026, 10:29 AM
Reporting Persons (10)
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Adams Street Partners, LLC | Investment Adviser | 3.90% | 3,275,616 | 3,275,616 | 0 |
| Adams Street 2012 Direct Fund LP | Partnership | 0.90% | 715,361 | 715,361 | 0 |
| Adams Street 2014 Direct Fund LP | Partnership | 0.90% | 736,033 | 736,033 | 0 |
| Adams Street 2011 Direct Fund LP | Partnership | 0.80% | 694,854 | 694,854 | 0 |
| Adams Street 2013 Direct Fund LP | Partnership | 0.60% | 541,133 | 541,133 | 0 |
| Adams Street Venture/Growth Fund VI LP | Partnership | 0.30% | 236,128 | 236,128 | 0 |
| Adams Street 2018 Direct Venture/Growth Fund LP | Partnership | 0.20% | 126,806 | 126,806 | 0 |
| Adams Street 2016 Direct Venture/Growth Fund LP | Partnership | 0.10% | 67,769 | 67,769 | 0 |
| Adams Street 2017 Direct Venture/Growth Fund LP | Partnership | 0.10% | 87,668 | 87,668 | 0 |
| Adams Street 2015 Direct Venture/Growth Fund LP | Partnership | 0.10% | 69,864 | 69,864 | 0 |
Disclosure Items (4)
Common Stock
Corvus Pharmaceuticals, Inc.
901 Gateway Boulevard, South San Francisco, CA, 94080
This Schedule 13D is being jointly filed by Adams Street Partners, LLC, Adams Street 2011 Direct Fund LP, Adams Street 2012 Direct Fund LP, Adams Street 2013 Direct Fund LP, Adams Street 2014 Direct Fund LP, Adams Street 2015 Direct Venture/Growth Fund LP, Adams Street 2016 Direct Venture/Growth Fund LP, Adams Street 2017 Direct Venture/Growth Fund LP, Adams Street 2018 Direct Venture/Growth Fund LP and Adams Street Venture/Growth Fund VI LP. Adams Street Partners, LLC is the managing member of the general partner of the general partner of each of the aforementioned funds and may be deemed to beneficially own the shares held by them.
The address of the principal offices of each of the filing entities is One North Wacker Drive, Suite 2700, Chicago, Illinois, 60606.
The principal occupation of each of the persons set forth on Schedule I hereto is the venture capital and growth equity investment business. The information set forth in Schedule I hereto is incorporated herein by reference.
None of the Reporting Persons have, and to the best of each Reporting Person's knowledge, during the last five years, each of the Reporting Persons has not, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activity subject to, federal or state securities laws or finding any violations with respect to such laws.
Each of the Reporting Persons is a United States citizen.
Item 5(a) of the Schedule 13D is hereby amended and restated in its entirety as follows: Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person. Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person.
Item 5(b) of the Schedule 13D is hereby amended and restated in its entirety as follows: Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting Person. Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person. Regarding sole power to dispose of shares, see Row 9 of the cover page of each Reporting Person. Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person.
Item 5(c) of the Schedule 13D is hereby amended and restated in its entirety as follows: The Reporting Persons have not effected any transaction in the Common Stock of the Issuer during the past 60 days.
Under certain circumstances set forth in the limited partnership agreements of the Reporting Persons, the general partner and limited partners of the reporting persons may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entities of which they are a partner.
Item 5(e) of the Schedule 13D is hereby amended and restated in its entirety as follows: January 23, 2026.
Item 7 of the Schedule 13D is hereby amended and restated in its entirety as follows: SCHEDULE I. EXHIBIT A. Form of Indemnification Agreement for Directors and Officers, incorporated herein by reference to Exhibit 10.4 to the Issuer's Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 1, 2018. EXHIBIT B. Amended and Restated Investors' Rights Agreement, dated September 16, 2015, by and among Corvus Pharmaceuticals, Inc. and the investors listed therein, incorporated herein by reference to Exhibit 4.3 to the Issuer's Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 1, 2018. EXHIBIT C. Joint Filing Agreement dated March 21, 2018 by and between the Reporting Persons, incorporated by reference to Exhibit C of the Schedule 13D.